KRAS and non-small cell lung carcinoma: Therefore, to solve this issue we decided to conduct a prospective study on plausible intratumor heterogeneity of KRAS oncogene point mutations at codon 12 in five different NSCLC samples from each cancer specimen, collected according to standardized protocol from 51 tumors after their complete surgical resection.